CMS Official Calls Medicare Price Negotiations An ‘Ongoing Conversation’
Executive Summary
The US Centers for Medicare & Medicaid Services’ Vinod Mitta discussed the agency’s latest thinking on the implementation of Medicare drug price negotiations at the Financial Times Pharma Summit.
You may also be interested in...
Medicare Seeks Input On Dispute Resolution, Civil Penalties For Rx Pricing Program
Calculating a ‘fair price’ for new versions of already negotiated moiety is also one of several that CMS is requesting input on in its recently released initial guidance on the negotiation program.
Pricing Disclosure Demands During Medicare Negotiation Process May Be Fodder For Lawsuits
Regulatory attorneys suggest different issues that might form the basis of manufacturer-sponsored litigation against the Centers for Medicare and Medicaid Services.
New Therapeutic Areas Ignite Investor Interest Amid Pandemic Reset
Investor attention is turning increasingly to new products and new areas of growth like obesity, Alzheimer’s disease and RSV as big blockbusters face increasing competitive pressure.